FDA honored by IoM
This article was originally published in The Tan Sheet
Executive Summary
The Institute of Medicine has made FDA Commissioner Mark McClellan, MD/PhD, and Deputy Commissioner Lester Crawford, PhD, its newest members, the agency announces Oct. 27. The holders of the agency's top two positions have never been asked to join the National Academy of Sciences division at the same time, FDA adds. "New IoM members are chosen worldwide on the basis of their distinguished professional achievement in a field related to medicine and health, and on their involvement in health care, disease prevention, education and research," FDA adds...
You may also be interested in...
Robust Trial Transparency Strategy Boosts Patient Engagement
Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.
Medtronic’s Perfusion System Recall Is Fifth Class I In 2 Months
The Bio-Console 560 extracorporeal blood pumping console is being recalled over reports it could lose power during bypass surgery, which could lead to organ or neural dysfunction, blood clots, or even death.
US House Co-signs Banking For Hemp Industry
House passes “SAFE Banking” Act sponsored by Rep. Ed Perlmutter to allow cannabis- and hemp-related businesses in states with some form of legalized marijuana to access financial services by creating protections for those institutions. Sen. Jeff Merkley introduced the same legislation in March.